174 related articles for article (PubMed ID: 35535057)
1. Rifaximin Vs. Norfloxacin for Spontaneous Bacterial Peritonitis Prophylaxis: A Randomized Controlled Trial.
Praharaj DL; Premkumar M; Roy A; Verma N; Taneja S; Duseja A; Dhiman RK
J Clin Exp Hepatol; 2022; 12(2):336-342. PubMed ID: 35535057
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of alternating norfloxacin and rifaximin as primary prophylaxis for spontaneous bacterial peritonitis in cirrhotic ascites: a prospective randomized open-label comparative multicenter study.
Assem M; Elsabaawy M; Abdelrashed M; Elemam S; Khodeer S; Hamed W; Abdelaziz A; El-Azab G
Hepatol Int; 2016 Mar; 10(2):377-85. PubMed ID: 26660707
[TBL] [Abstract][Full Text] [Related]
3. Randomized-controlled trial of rifaximin versus norfloxacin for secondary prophylaxis of spontaneous bacterial peritonitis.
Elfert A; Abo Ali L; Soliman S; Ibrahim S; Abd-Elsalam S
Eur J Gastroenterol Hepatol; 2016 Dec; 28(12):1450-1454. PubMed ID: 27512927
[TBL] [Abstract][Full Text] [Related]
4. Safety and Efficacy of Rifaximin in Prophylaxis of Spontaneous Bacterial Peritonitis: A Systematic Review and Meta-analysis.
Menshawy A; Mattar O; Barssoum K; AboEl-Naga AM; Salim HM; Mohamed AMF; Elgebaly A; Abd-Elsalam S
Curr Drug Targets; 2019; 20(4):380-387. PubMed ID: 30246636
[TBL] [Abstract][Full Text] [Related]
5. Addition of probiotics to norfloxacin does not improve efficacy in the prevention of spontaneous bacterial peritonitis: a double-blind placebo-controlled randomized-controlled trial.
Pande C; Kumar A; Sarin SK
Eur J Gastroenterol Hepatol; 2012 Jul; 24(7):831-9. PubMed ID: 22522141
[TBL] [Abstract][Full Text] [Related]
6. Daily Norfloxacin vs. Weekly Ciprofloxacin to Prevent Spontaneous Bacterial Peritonitis: A Randomized Controlled Trial.
Yim HJ; Suh SJ; Jung YK; Yim SY; Seo YS; Lee YR; Park SY; Jang JY; Kim YS; Kim HS; Kim BI; Um SH
Am J Gastroenterol; 2018 Aug; 113(8):1167-1176. PubMed ID: 29946179
[TBL] [Abstract][Full Text] [Related]
7. Antibiotics for prophylaxis of spontaneous bacterial peritonitis: systematic review & Bayesian network meta-analysis.
Soni H; Kumar-M P; Sharma V; Bellam BL; Mishra S; Mahendru D; Mandavdhare HS; Medhi B; Dutta U; Singh V
Hepatol Int; 2020 May; 14(3):399-413. PubMed ID: 32266675
[TBL] [Abstract][Full Text] [Related]
8. Norfloxacin and cisapride combination decreases the incidence of spontaneous bacterial peritonitis in cirrhotic ascites.
Sandhu BS; Gupta R; Sharma J; Singh J; Murthy NS; Sarin SK
J Gastroenterol Hepatol; 2005 Apr; 20(4):599-605. PubMed ID: 15836710
[TBL] [Abstract][Full Text] [Related]
9. Antibiotic prophylaxis to prevent spontaneous bacterial peritonitis in people with liver cirrhosis: a network meta-analysis.
Komolafe O; Roberts D; Freeman SC; Wilson P; Sutton AJ; Cooper NJ; Pavlov CS; Milne EJ; Hawkins N; Cowlin M; Thorburn D; Davidson BR; Tsochatzis E; Gurusamy KS
Cochrane Database Syst Rev; 2020 Jan; 1(1):CD013125. PubMed ID: 31978256
[TBL] [Abstract][Full Text] [Related]
10. The role of rifaximin in the primary prophylaxis of spontaneous bacterial peritonitis in patients with liver cirrhosis.
Hanouneh MA; Hanouneh IA; Hashash JG; Law R; Esfeh JM; Lopez R; Hazratjee N; Smith T; Zein NN
J Clin Gastroenterol; 2012 Sep; 46(8):709-15. PubMed ID: 22878533
[TBL] [Abstract][Full Text] [Related]
11. Norfloxacin versus alternative antibiotics for prophylaxis of spontaneous bacteria peritonitis in cirrhosis: a systematic review and meta-analysis.
Song S; Yang Y; Geng C; Tang Z; Wang C; Li X
BMC Infect Dis; 2023 Aug; 23(1):557. PubMed ID: 37641014
[TBL] [Abstract][Full Text] [Related]
12. Impact of rifaximin on the frequency and characteristics of spontaneous bacterial peritonitis in patients with liver cirrhosis and ascites.
Lutz P; Parcina M; Bekeredjian-Ding I; Nischalke HD; Nattermann J; Sauerbruch T; Hoerauf A; Strassburg CP; Spengler U
PLoS One; 2014; 9(4):e93909. PubMed ID: 24714550
[TBL] [Abstract][Full Text] [Related]
13. The role of rifaximine in the prevention of the spontaneous bacterial peritonitis.
Dănulescu RM; Ciobică A; Stanciu C; Trifan A
Rev Med Chir Soc Med Nat Iasi; 2013; 117(2):315-20. PubMed ID: 24340510
[TBL] [Abstract][Full Text] [Related]
14. Primary prophylaxis of spontaneous bacterial peritonitis delays hepatorenal syndrome and improves survival in cirrhosis.
Fernández J; Navasa M; Planas R; Montoliu S; Monfort D; Soriano G; Vila C; Pardo A; Quintero E; Vargas V; Such J; Ginès P; Arroyo V
Gastroenterology; 2007 Sep; 133(3):818-24. PubMed ID: 17854593
[TBL] [Abstract][Full Text] [Related]
15. The efficacy and the immunomodulatory effect of rifaximin in prophylaxis of spontaneous bacterial peritonitis in cirrhotic Egyptian patients.
Mostafa T; Badra G; Abdallah M
Turk J Gastroenterol; 2015 Mar; 26(2):163-9. PubMed ID: 25835116
[TBL] [Abstract][Full Text] [Related]
16. Rifaximin versus norfloxacin for prevention of spontaneous bacterial peritonitis: a systematic review.
Sidhu GS; Go A; Attar BM; Mutneja HR; Arora S; Patel SA
BMJ Open Gastroenterol; 2017; 4(1):e000154. PubMed ID: 28944070
[TBL] [Abstract][Full Text] [Related]
17. The Risk of
Girleanu I; Trifan A; Huiban L; Muzica C; Nemteanu R; Teodorescu A; Singeap AM; Cojocariu C; Chiriac S; Petrea O; Zenovia S; Nastasa R; Cuciureanu T; Stanciu C
Medicina (Kaunas); 2021 Sep; 57(9):. PubMed ID: 34577887
[No Abstract] [Full Text] [Related]
18. Low-dose rifaximin prevents complications and improves survival in patients with decompensated liver cirrhosis.
Zeng X; Sheng X; Wang PQ; Xin HG; Guo YB; Lin Y; Zhong JW; He CZ; Yin J; Liu TT; Ma WJ; Xiao X; Shi PM; Yuan ZL; Yang L; Ma X; Xu JM; Shen XZ; Yang CQ; Zhu X; Lv NH; Xie WF
Hepatol Int; 2021 Feb; 15(1):155-165. PubMed ID: 33385299
[TBL] [Abstract][Full Text] [Related]
19. Rifaximin has the potential to prevent complications of cirrhosis.
Flamm SL; Mullen KD; Heimanson Z; Sanyal AJ
Therap Adv Gastroenterol; 2018; 11():1756284818800307. PubMed ID: 30283499
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of Norfloxacin Prophylaxis to Prevent Spontaneous Bacterial Peritonitis: A Systematic Review and Meta-Analysis.
Mücke MM; Mücke VT; Graf C; Schwarzkopf KM; Ferstl PG; Fernandez J; Zeuzem S; Trebicka J; Lange CM; Herrmann E
Clin Transl Gastroenterol; 2020 Aug; 11(8):e00223. PubMed ID: 32955202
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
